{
  "main_header": {
    "sid": 664761,
    "name": "Sanofi India",
    "stock_name": "Sanofi India",
    "full_name": "Sanofi India Ltd",
    "name_url": "stocks-analysis/sanofi-india",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "4,312.95",
    "chg": -58.75,
    "chgp": "-1.34%",
    "dir": -1,
    "prev_price": "4,371.70",
    "mcapval": "9,932.99 Cr",
    "mcap": "Small Cap",
    "scripcode": 500674,
    "symbol": "SANOFI",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE058A01010",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "8.89 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sanofi-india-664761-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Sanofi India’s Evaluation Metrics Revised Amidst Challenging Market Performance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sanofi-india-downgraded-to-sell-by-marketsmojo-amid-weak-financial-and-technical-trends-3733125",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanofiIndia_mojoScore_3733125.png",
        "date": "2025-11-27 10:06:18",
        "description": "Sanofi India has experienced a revision in its evaluation metrics reflecting a shift in market assessment, influenced by recent financial trends and technical indicators. The pharmaceutical company’s performance data and sector context provide insight into the factors shaping this change."
      },
      {
        "title": "Why is Sanofi India falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sanofi-india-fallingrising-3726759",
        "imagepath": "",
        "date": "2025-11-25 00:51:01",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>On 24 November, Sanofi India’s shares closed at ₹4,398, down ₹111.3 or 2.47% from the previous session. This decline continues a five-day losing streak during which the stock has dropped 4.75%. Intraday, the share price touched a low of ₹4,370, marking a 3.09% dip. The weighted average price indicates that a larger volume of shares traded closer to the day’s low, signalling selling pressure. Furthermore, the stock is trading below all key moving averages – the 5-day, 20-day, 50-day, 100-day, and 200-day – underscoring a bearish technical trend.</p>\n<p>Investor participation appears to be waning, with delivery volumes on 21 November falling by 26.06% compared to the five-day average. This decline in investor engagement may be contri..."
      },
      {
        "title": "Sanofi India Hits 52-Week Low, Trading at Rs 33.05",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sanofi-india-hits-52-week-low-trading-at-rs-3305-3690254",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanofiIndia_priceRelatedfactors_3690254.png",
        "date": "2025-11-11 18:01:57",
        "description": "Sanofi India has reached a 52-week low, reflecting a challenging period with a significant decline over the past year. The stock is trading below key moving averages, although it maintains a high dividend yield and strong management efficiency. Long-term growth prospects appear subdued amid negative sales and profit trends."
      },
      {
        "title": "Has Sanofi India declared dividend?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/has-sanofi-india-declared-dividend-3660082",
        "imagepath": "",
        "date": "2025-10-30 23:34:13",
        "description": "Sanofi India Ltd has declared a dividend.\n\nDividend Details:\n- Percentage announced: 750%\n- Amount per share: 117\n- Ex-date: 07 Nov 25\n\nDividend Yield: 2.47%.\n\nTotal Returns by Period:\nIn the last 3 months, the price return was -18.68%, the dividend return was 1.35%, resulting in a total return of -17.33%.\n\nOver the past 6 months, the price return was -18.91%, the dividend return was 1.28%, leading to a total return of -17.63%.\n\nFor the 1-year period, the price return was -26.88%, with a dividend return of 2.88%, culminating in a total return of -24.0%.\n\nIn the 2-year period, the price return was -35.48%, the dividend return was 4.63%, resulting in a total return of -30.85%.\n\nDuring the last 3 years, the price return was -13.85%, the dividend return was 9.68%, leading to a total return of -4.17%.\n\nOver the 4-year period, the price return was -42.23%, with a dividend return of 12.88%, resulting in a total re..."
      },
      {
        "title": "How has been the historical performance of Sanofi India?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-sanofi-india-3656704",
        "imagepath": "",
        "date": "2025-10-29 22:43:16",
        "description": "Answer:\nThe historical performance of Sanofi India shows a mixed trend in its financial metrics for the years ending December 2023 and December 2024.\n\nBreakdown:\nIn the fiscal year ending December 2024, Sanofi India reported net sales of 2,013.20 crore, a slight increase from 1,996.10 crore in December 2023. Total operating income also rose to 2,013.20 crore from 1,996.10 crore. However, total expenditure increased to 1,522.40 crore from 1,508.40 crore, leading to an operating profit (PBDIT) of 507.30 crore, down from 548.90 crore the previous year. Profit before tax decreased to 431.40 crore from 528.50 crore, and profit after tax fell to 313.70 crore from 364.60 crore. The consolidated net profit also declined to 413.30 crore from 602.90 crore. Earnings per share dropped to 179.7 from 262.13, reflecting a decrease in profitability. On the balance sheet, total liabilities decreased to 1,611.70 crore from 1..."
      },
      {
        "title": "Are Sanofi India latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-sanofi-india-latest-results-good-or-bad-3656319",
        "imagepath": "",
        "date": "2025-10-29 19:19:20",
        "description": "Sanofi India's latest financial results for Q2 FY26 present a complex picture, highlighting both operational challenges and strengths. The company reported net sales of ₹524.00 crores, which reflects a slight decline of 1.74% compared to the previous quarter, although it shows a year-on-year growth of 6.79% from ₹490.70 crores in Q2 FY25. This indicates some resilience in sales performance despite recent volatility.\n\nIn terms of profitability, the standalone net profit for Q2 FY26 was ₹82.20 crores, representing a sequential improvement of 11.07% from the previous quarter. However, this figure marks a significant year-on-year decline of 45.89%, raising concerns about the sustainability of earnings quality. The operating margin remained relatively stable at 22.84%, slightly down from 22.98% in Q1 FY26, which suggests that while the company is managing its costs effectively, it faces pressure from pricing and..."
      },
      {
        "title": "Sanofi India Q2 FY26: Margin Resilience Masks Profitability Decline Amid Sector Headwinds",
        "link": "https://www.marketsmojo.com/news/result-analysis/sanofi-india-q2-fy26-margin-resilience-masks-profitability-decline-amid-sector-headwinds-3656172",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/SanofiIndia_quaterlyResult_3656172.png",
        "date": "2025-10-29 15:16:25",
        "description": "Sanofi India Ltd., one of India's leading multinational pharmaceutical companies, posted consolidated net profit of ₹82.20 crores in Q2 FY26, marking an 11.07% sequential increase from Q1 FY26 but a stark 45.89% year-on-year decline. The Mumbai-based drugmaker, with a market capitalisation of ₹11,089 crores, continues to face mounting profitability pressures despite maintaining operational efficiency. The stock has suffered significantly, declining 26.38% over the past year and currently trading at ₹4,730.40, approximately 30.80% below its 52-week high of ₹6,836.00."
      },
      {
        "title": "When is the next results date for Sanofi India?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-sanofi-india-3645075",
        "imagepath": "",
        "date": "2025-10-24 23:15:50",
        "description": "Sanofi India will declare its results on 29 October 2025...."
      },
      {
        "title": "Why is Sanofi India falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sanofi-india-fallingrising-3580249",
        "imagepath": "",
        "date": "2025-09-29 21:51:43",
        "description": "As of 29-Sep, Sanofi India Ltd's stock price is currently at 4,709.00, reflecting a decrease of 41.1 points or 0.87%. The stock has been on a downward trend, having underperformed its sector by 1.01% today and experiencing a consecutive fall for the last eight days, resulting in a total decline of 6.95% during this period. Over the past year, the stock has generated a return of -30.75%, while its profits have decreased by 9.4%. Despite high management efficiency indicated by a return on equity (ROE) of 35.83% and a low debt-to-equity ratio, the stock is trading at a premium compared to its peers, which may be contributing to its recent price decline.\n\nIn the broader market context, Sanofi India's short-term performance has been notably worse than the benchmark, with a 1-week return of -6.09% compared to the Sensex's -2.18%. This underperformance is further highlighted by the stock's long-term struggles, inc..."
      }
    ],
    "total": 164,
    "sid": "664761",
    "stock_news_url": "https://www.marketsmojo.com/news/sanofi-india-664761"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "18-Nov-2025",
      "details": "Please find enclosed copies of the Newspaper publication of Postal Ballot Notice of the Company published on 18th November 2025 in Business Standard and Sakal newspapers.",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Notice of Postal Ballot",
      "datetime": "17-Nov-2025",
      "details": "The Notice of Postal Ballot for appointment of Managing Director is enclosed.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "04-Nov-2025",
      "details": "Please find enclosed transcript of Investor/Analysts call held on 29th October 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sanofi India Ltd has declared <strong>750%</strong> dividend, ex-date: 07 Nov 25",
          "dt": "2025-11-07",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Sanofi India’s Evaluation Metrics Revised Amidst Challenging Market Performance

2025-11-27 10:06:18

Sanofi India has experienced a revision in its evaluation metrics reflecting a shift in market assessment, influenced by recent financial trends and technical indicators. The pharmaceutical company’s performance data and sector context provide insight into the factors shaping this change.

Read More

Why is Sanofi India falling/rising?

2025-11-25 00:51:01

Recent Price Movement and Market Performance

On 24 November, Sanofi India’s shares closed at ₹4,398, down ₹111.3 or 2.47% from the previous session. This decline continues a five-day losing streak during which the stock has dropped 4.75%. Intraday, the share price touched a low of ₹4,370, marking a 3.09% dip. The weighted average price indicates that a larger volume of shares traded closer to the day’s low, signalling selling pressure. Furthermore, the stock is trading below all key moving averages – the 5-day, 20-day, 50-day, 100-day, and 200-day – underscoring a bearish technical trend.

Investor participation appears to be waning, with delivery volumes on 21 November falling by 26.06% compared to the five-day average. This decline in investor engagement may be contri...

Read More

Sanofi India Hits 52-Week Low, Trading at Rs 33.05

2025-11-11 18:01:57

Sanofi India has reached a 52-week low, reflecting a challenging period with a significant decline over the past year. The stock is trading below key moving averages, although it maintains a high dividend yield and strong management efficiency. Long-term growth prospects appear subdued amid negative sales and profit trends.

Read More

Has Sanofi India declared dividend?

2025-10-30 23:34:13

Sanofi India Ltd has declared a dividend. Dividend Details: - Percentage announced: 750% - Amount per share: 117 - Ex-date: 07 Nov 25 Dividend Yield: 2.47%. Total Returns by Period: In the last 3 months, the price return was -18.68%, the dividend return was 1.35%, resulting in a total return of -17.33%. Over the past 6 months, the price return was -18.91%, the dividend return was 1.28%, leading to a total return of -17.63%. For the 1-year period, the price return was -26.88%, with a dividend return of 2.88%, culminating in a total return of -24.0%. In the 2-year period, the price return was -35.48%, the dividend return was 4.63%, resulting in a total return of -30.85%. During the last 3 years, the price return was -13.85%, the dividend return was 9.68%, leading to a total return of -4.17%. Over the 4-year period, the price return was -42.23%, with a dividend return of 12.88%, resulting in a total re...

Read More

How has been the historical performance of Sanofi India?

2025-10-29 22:43:16

Answer: The historical performance of Sanofi India shows a mixed trend in its financial metrics for the years ending December 2023 and December 2024. Breakdown: In the fiscal year ending December 2024, Sanofi India reported net sales of 2,013.20 crore, a slight increase from 1,996.10 crore in December 2023. Total operating income also rose to 2,013.20 crore from 1,996.10 crore. However, total expenditure increased to 1,522.40 crore from 1,508.40 crore, leading to an operating profit (PBDIT) of 507.30 crore, down from 548.90 crore the previous year. Profit before tax decreased to 431.40 crore from 528.50 crore, and profit after tax fell to 313.70 crore from 364.60 crore. The consolidated net profit also declined to 413.30 crore from 602.90 crore. Earnings per share dropped to 179.7 from 262.13, reflecting a decrease in profitability. On the balance sheet, total liabilities decreased to 1,611.70 crore from 1...

Read More

Are Sanofi India latest results good or bad?

2025-10-29 19:19:20

Sanofi India's latest financial results for Q2 FY26 present a complex picture, highlighting both operational challenges and strengths. The company reported net sales of ₹524.00 crores, which reflects a slight decline of 1.74% compared to the previous quarter, although it shows a year-on-year growth of 6.79% from ₹490.70 crores in Q2 FY25. This indicates some resilience in sales performance despite recent volatility. In terms of profitability, the standalone net profit for Q2 FY26 was ₹82.20 crores, representing a sequential improvement of 11.07% from the previous quarter. However, this figure marks a significant year-on-year decline of 45.89%, raising concerns about the sustainability of earnings quality. The operating margin remained relatively stable at 22.84%, slightly down from 22.98% in Q1 FY26, which suggests that while the company is managing its costs effectively, it faces pressure from pricing and...

Read More

Sanofi India Q2 FY26: Margin Resilience Masks Profitability Decline Amid Sector Headwinds

2025-10-29 15:16:25

Sanofi India Ltd., one of India's leading multinational pharmaceutical companies, posted consolidated net profit of ₹82.20 crores in Q2 FY26, marking an 11.07% sequential increase from Q1 FY26 but a stark 45.89% year-on-year decline. The Mumbai-based drugmaker, with a market capitalisation of ₹11,089 crores, continues to face mounting profitability pressures despite maintaining operational efficiency. The stock has suffered significantly, declining 26.38% over the past year and currently trading at ₹4,730.40, approximately 30.80% below its 52-week high of ₹6,836.00.

Read More

When is the next results date for Sanofi India?

2025-10-24 23:15:50

Sanofi India will declare its results on 29 October 2025....

Read More

Why is Sanofi India falling/rising?

2025-09-29 21:51:43

As of 29-Sep, Sanofi India Ltd's stock price is currently at 4,709.00, reflecting a decrease of 41.1 points or 0.87%. The stock has been on a downward trend, having underperformed its sector by 1.01% today and experiencing a consecutive fall for the last eight days, resulting in a total decline of 6.95% during this period. Over the past year, the stock has generated a return of -30.75%, while its profits have decreased by 9.4%. Despite high management efficiency indicated by a return on equity (ROE) of 35.83% and a low debt-to-equity ratio, the stock is trading at a premium compared to its peers, which may be contributing to its recent price decline. In the broader market context, Sanofi India's short-term performance has been notably worse than the benchmark, with a 1-week return of -6.09% compared to the Sensex's -2.18%. This underperformance is further highlighted by the stock's long-term struggles, inc...

Read More

View All News